The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

Compositions of pro-chelator compounds are described herein. The pro-chelators may be activated in reducing conditions, such as in the intracellular space, so as to sequester metals such as iron. The pro-chelators may be used to target malignant cells or in the treatment in a condition associated with metal ion disregulation.

Compositions of pro-chelator compounds are described herein. The pro-chelators may be activated in reducing conditions, such as in the intracellular space, so as to sequester metals such as iron. The pro-chelators may be used to target malignant cells or in the treatment in a condition associated with metal ion disregulation.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising an NLRP3 antagonist. In some aspects, the NLRP3 antagonist comprises an antisense oligonucleotide (ASO). Also provided herein are methods for producing the exosomes and methods for using the exosomes to treat and/or prevent diseases or disorders.

The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising an NLRP3 antagonist. In some aspects, the NLRP3 antagonist comprises an antisense oligonucleotide (ASO). Also provided herein are methods for producing the exosomes and methods for using the exosomes to treat and/or prevent diseases or disorders.

In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured: Formulae (I) and (II), wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein. ##STR00001##

In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured: Formulae (I) and (II), wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein. ##STR00001##

Compositions of furan based surfactants derived from unsaturated carbon-containing molecules, such as fatty acids, as well as methods for forming furan based surfactants from unsaturated carbon-containing molecules, such as fatty acids, are disclosed herein. These compositions and methods can utilize long-chain (e.g., C14-C26) unsaturated carbon-containing molecules, for instance unsaturated fatty acids such as oleic acid or methyl oleate from soybean oil, to derive oleo-furan surfactants. To facilitate this, certain such embodiments include reaction steps that cleave the reactant molecule (e.g., methyl oleate) at the double bond and subsequently oxidize products to form a carboxylic acid molecule and a dicarboxylic acid molecule. In such embodiments, these two acids can be subsequently acylated with furan and functionalized to form surfactants.

Compositions of furan based surfactants derived from unsaturated carbon-containing molecules, such as fatty acids, as well as methods for forming furan based surfactants from unsaturated carbon-containing molecules, such as fatty acids, are disclosed herein. These compositions and methods can utilize long-chain (e.g., C14-C26) unsaturated carbon-containing molecules, for instance unsaturated fatty acids such as oleic acid or methyl oleate from soybean oil, to derive oleo-furan surfactants. To facilitate this, certain such embodiments include reaction steps that cleave the reactant molecule (e.g., methyl oleate) at the double bond and subsequently oxidize products to form a carboxylic acid molecule and a dicarboxylic acid molecule. In such embodiments, these two acids can be subsequently acylated with furan and functionalized to form surfactants.